from june 1984 through january 1985 , 56 patients with limited-extent sclc were enrolled in a cancer and leukemia group b ( calgb ) phase ii study using five cycles of cyclophosphamide ( 500 mg/m2 intravenously [ iv ] day 1 ) , etoposide ( 80 mg/m2 iv days 1 to 3 ) , and cisplatin ( 33 mg/m2 iv days 1 to 3 ) administered at 3-week intervals ( cep ) , with radiation therapy ( 50 gy to chest and 30 gy to brain ) administered concomitant with cycles 4 and 5 , followed by three cycles of cyclophosphamide ( 500 mg/m2 iv day 1 ) , etoposide ( 80 mg/m2 iv days 1 to 3 ) , and doxorubicin ( 50 mg/m2 iv day 1 ) .
C0149925
sclc
C0817096
chest